Tech Company Financing Transactions
Hemab Therapeutics Funding Round
Hemab Therapeutics secured a $135 million Series B venture capital round on 2/21/2023. Investors included Access Biotechnology, Avoro Ventures and Deep Track Capital.
Transaction Overview
Company Name
Announced On
2/21/2023
Transaction Type
Venture Equity
Amount
$135,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to support the Phase 1/2 study of bispecific antibody HMB-001 in Glanzmann Thrombasthenia, continue of pivotal studies, complete of Phase 1/2 study of HMB-VWF in von Willebrand Disease, as well as future pipeline evolution.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
125 Cambridge Park Dr
Cambridge, MA 02140
USA
Cambridge, MA 02140
USA
Phone
Undisclosed
Website
Email Address
Overview
Hemab Therapeutics ApS is an emerging biotech company supported by Novo Holdings A/S with the aim of developing novel treatments for rare and underserved bleeding disorders. Based in Copenhagen, the company is led by a team of drug developers and scientists with deep expertise in haemophilia. Hemab has exclusive licences to state-of-the-art antibody technologies from both Novo Nordisk A/S and Genmab A/S.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Benny Sorensen
Chief Financial Officer
Mads Behrndt?
Chief Technical Officer
Johan Faber
Browse more venture capital transactions:
Prev: 2/21/2023: Strive venture capital transaction
Next: 2/21/2023: Current Surgical venture capital transaction
Share this article
Where The Data Comes From
We record every notable VC transaction. VC investment data records on this site are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs